logo

For the Inventor, By the Inventor

Ghent, Belgium

Innogenetics N.v.

Calculating rank
USPTO Granted Patents = 82

% Expired Patents = 35.4



Trademarks = 2

Forward Citations = 832

Loading Chart...
Loading Chart...

99 inventors (with patents filed for the assignee):

goldMedal Geert Maertens (25 out of 42 patents)

silverMedal Rudi Rossau (23 out of 35 patents)

bronzeMedal Hugo Van Heuverswyn (17 out of 27 patents)

4.  Lieven Jozef Stuyver (12 out of 30 patents)

5.  Geert Jannes (9 out of 11 patents)

6.  Eric Saman (9 out of 10 patents)

7.  Erik Depla (8 out of 37 patents)

8.  Fons Bosman (8 out of 9 patents)

9.  Erwin Sablon (7 out of 12 patents)

10.  Marie-Ange Buyse (6 out of 61 patents)

11.  Eugeen Vanmechelen (6 out of 17 patents)

12.  Dirk Pollet (6 out of 6 patents)

13.  Hugo Van Heuverswijn (6 out of 6 patents)

14.  Robert De Leys (6 out of 12 patents)

15.  Bart Vanderborght (6 out of 6 patents)


Core Competencies:
HCV Typing
Antibodies
Viral Diagnostics
Drug Resistance
Nucleic Acid Probes
Immunoassays
Peptide Antigens
HIV Mutations
Neurological Disease Diagnosis
Fungal Pathogens
Epitopes
Synthetic Antigens

82 patents:

1. 8686126 - HBV drug resistance methods (2014-04-01),
2. 8426129 - Method for typing HLA alleles (2013-04-23),
3. 8343493 - Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs (2013-01-01),
4. 8278432 - HBV drug resistance methods (2012-10-02),
5. 8124747 - HCV clade and prototype sequences thereof (2012-02-28),
6. 8101351 - Process for typing of HCV isolates (2012-01-24),
7. 7955883 - Polymer replicated interdigitated electrode array for (bio) sensing applications (2011-06-07),
8. 7741461 - Nucleic acid probes and methods for detecting clinically important fungal pathogens (2010-06-22),
9. 7422848 - Hepatitis-B viral variants with reduced susceptibility to nucleoside analogs and uses thereof (2008-09-09),
10. 7413741 - HCV E1 comprising specific disulfide bridges (2008-08-19),
11. 7390623 - [object Object] (2008-06-24),
12. 7387879 - Diagnosis of tauopathies (2008-06-17),
13. 7314925 - Constructs and methods for expression of recombinant HCV envelope proteins (2008-01-01),
14. 7313357 - Method for typing and detecting HBV (2007-12-25),
15. 7258977 - Process for typing of HCV isolates (2007-08-21),
Company Overview
Innogenetics N.V., based in Ghent, Belgium, specializes in the research and development of innovative solutions for hepatitis C. The company focuses on advanced technologies in viral diagnostics, including HCV typing and drug resistance testing. Its expertise extends to the development of nucleic acid probes, immunoassays, and peptide antigens, contributing significantly to the understanding and management of viral infections. Innogenetics is committed to enhancing patient outcomes through cutting-edge research and diagnostic tools.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Innogenetics N.v. USPTO Patent Assignee Logo
82 Patents

#3 in Ghent

#64 in Belgium

#9,267 in the World

Ghent, BE
Ghent, Belgium

Innogenetics N.v.

Forward Citations = 832

99 inventors:

goldMedal Geert Maertens (25 out of 42 patents)

silverMedal Rudi Rossau (23 out of 35 patents)

bronzeMedal Hugo Van Heuverswyn (17 out of 27 patents)

4.  Lieven Jozef Stuyver (12 out of 30 patents)

5.  Geert Jannes (9 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Innogenetics N.v.. Retrieved from https://idiyas.com/company/innogenetics-n-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…